MicroRNA-449a Is Downregulated in Non-Small Cell Lung Cancer and Inhibits Migration and Invasion by Targeting c-Met

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Luo, Wenting ^a   Huang, Bo ^b   Li, Zixuan ^a   Li, Haiying ^a   Sun, Limei ^a   Zhang, Qingfu ^a   Qiu, Xueshan ^a   Wang, Enhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 449A; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

3' UNTRANSLATED REGIONS; ADULT; AGED; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE; CELL MOVEMENT; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84878466503     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064759     Document Type: Article

References (39)

1. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 101: 2999-3004.
2. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102: 13944-13949.
3. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT, (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435: 839-843.
4. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, et al. (2005) RAS is regulated by the let-7 microRNA family. Cell 120: 635-647.
5. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
6. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
7. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, et al. (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756.
8. Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, et al. (2010) Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 10: 318.
9. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, et al. (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13: 48-57.
10. Yang J, Lan H, Huang X, Liu B, Tong Y, (2012) MicroRNA-126 inhibits tumor cell growth and its expression level correlates with poor survival in non-small cell lung cancer patients. PLoS One 7: e42978.
11. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, et al. (2009) MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res 69: 5776-5783.
12. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, et al. (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28: 1714-1724.
13. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, et al. (2011) miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer 10: 29.
14. Chen H, Lin YW, Mao YQ, Wu J, Liu YF, et al. (2012) MicroRNA-449a acts as a tumor suppressor in human bladder cancer through the regulation of pocket proteins. Cancer Lett 320: 40-47.
15. Jeon HS, Lee SY, Lee EJ, Yun SC, Cha EJ, et al. (2012) Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. Lung Cancer 76: 171-176.
16. Yang X, Feng M, Jiang X, Wu Z, Li Z, et al. (2009) miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev 23: 2388-2393.
17. Lize M, Pilarski S, Dobbelstein M, (2010) E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ 17: 452-458.
18. Feng M, Yu Q, (2010) miR-449 regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit. Cell Cycle 9: 213-214.
19. Noonan EJ, Place RF, Basak S, Pookot D, Li LC, (2010) miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget 1: 349-358.
20. Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, et al. (2007) Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 67: 6092-6099.
21. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
22. Liang Y, Ridzon D, Wong L, Chen C, (2007) Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 8: 166.
23. Liang Y, (2008) An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics 1: 61.
24. Wang Z, Chen Z, Gao Y, Li N, Li B, et al. (2011) DNA hypermethylation of microRNA-34b/c has prognostic value for stage non-small cell lung cancer. Cancer Biol Ther 11: 490-496.
25. Tanaka N, Toyooka S, Soh J, Kubo T, Yamamoto H, et al. (2012) Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer. Lung Cancer 76: 32-38.
26. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, et al. (2009) miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 30: 1903-1909.
27. Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, et al. (2008) Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 134: 521-533.
28. Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, et al. (2008) Chromatin structure analyses identify miRNA promoters. Genes Dev 22: 3172-3183.
29. Buurman R, Gurlevik E, Schaffer V, Eilers M, Sandbothe M, et al. (2012) Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143: 811-820 e811-815.
30. Gherardi E, Stoker M, (1990) Hepatocytes and scatter factor. Nature 346: 228.
31. Peruzzi B, Bottaro DP, (2006) Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657-3660.
32. Olivero M, Rizzo M, Madeddu R, Casadio C, Pennacchietti S, et al. (1996) Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 74: 1862-1868.
33. Comoglio PM, Boccaccio C, (2001) Scatter factors and invasive growth. Semin Cancer Biol 11: 153-165.
34. Jiang W, Hiscox S, Matsumoto K, Nakamura T, (1999) Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 29: 209-248.
35. Jiang WG, Grimshaw D, Lane J, Martin TA, Abounader R, et al. (2001) A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 7: 2555-2562.
36. Ichimura E, Maeshima A, Nakajima T, Nakamura T, (1996) Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. Jpn J Cancer Res 87: 1063-1069.
37. Siegfried JM, Weissfeld LA, Singh-Kaw P, Weyant RJ, Testa JR, et al. (1997) Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res 57: 433-439.
38. Ma PC, Maulik G, Christensen J, Salgia R, (2003) c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22: 309-325.
39. Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, et al. (2012) HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res 18: 209-218.